Although the head and neck glandular cystic cancer (ACC) is rare, it constitutes a major challenge due to its local recurrence and metastasis. Although growth is usually slow, ACC usually lacks effective treatment options, especially for recurrence or metastasis. Recently, a group of researchers led by Dr. Yoshihito Kano discussed the efficacy of immunotherapy in the contribution of Dr. Takahiro Naito of Tokyo Medical and Dental University, especially the immune examination point inhibitor (ICIS), and a comprehensive genome analysis (CGP. ) Practical. In managing this powerful disease. Their discovery was published in the magazine of “Medical Magazine”, clarifying the potential role of ICIS and the importance of identifying personalized therapy in ACC.
Dr. Kano and his colleagues from TMDU checked a national database, including hundreds of cases of head and neck ACC. This research is one of the most widely analyzes in similar studies, providing insights on the real application of ICI in ACC patients. The results showed that although ICIS showed hope, its effect was limited, and the purpose of the purpose of the purpose (ORR) and about half of the patients performed disease control. These numbers emphasize that more exquisite biomarkers are required to predict which patients may benefit from ICI therapy.
The group also analyzes tumor mutation burden (TMB), which is usually better related to other cancers’ response to ICI. However, in the case of ACC, it is found that TMB is relatively low, which may explain that ICI’s effectiveness among the crowd is limited. Interestingly, some patients with specific genetic changes (such as MYB structure mutations) have better response to ICIS, which indicates that these variants can be used as potential predictive biomarkers for ACC immunotherapy.
Dr. Kano emphasized the importance of these discoveries and pointed out: “Our research emphasizes comprehensive genomic analysis in identifying the importance of potential biomarkers that can be predicted by ACC patients. The response is moderate, but some genetic features (such as MyB variants) may provide a line of hope for more effective treatment strategies. “
In detailed analysis, researchers have determined several general mutations in ACC patients including NOTCH1, KDM6A and MYB. Among them, the MyB structure variant has become a particularly interesting candidate for further research. The study reports that patients with MYB structure mutations are more favorable to ICIS.
A compelling case involves a male patient with a 63 -year -old male suffering from mandibular glandular tumors. After treatment with ICI PEMBROLIZUMAB, it shows long -term stable diseases. The patient has a MyB structure variant and other mutations, but manifests the response to the treatment for one and a half years. This case emphasizes the potential of MyB as a biomarker that chooses to benefit from immunotherapy.
The study also pointed out that due to tumor molecules and histological characteristics, such as immunogenicity and less tumor infiltrating lymphocytes, using ICI to treat ACC challenges. Although these factors are limited in other types of head cancer. However, the team remained optimistic about the future of personalized medicine in ACC treatment, and advocated further research to verify these discoveries and explore new treatment pathways.
In short, this comprehensive analysis of Dr. KANO and his team represents an important step in understanding the role of immunotherapy in the treatment of head and neck ACC. The MYB structure variant is identified as a potential biomarker, providing a new direction for personalized therapy strategies, and brings hope for patients with almost no choice. With the continuous development of precision medicine, such research is essential for rare and challenging cancer development for ACCs.
Journal reference
Naito, T., Noji, R., Kugimoto, T., Kuroshima, T., Tomioka, H., FujiWara, S., Suenaga, M., Harada, H. And kano, y. (2023). Immunotherapy and comprehensive genomic analysis of clinical practical effects of cystic carcinoma in the brain gland. Medicina, 59, 2111. Doi: https: //doi.org/10.3390/medicina591221111
About the author
Dr. Yoshihito Kano He is an outstanding primary associate professor of Tokyo Medical and Dental University (TMDU). He specializes in medical oncology, cancer genome medicine and targeted therapy. Dr. Kano’s academic journey began at TMDU, and he obtained a medical degree in 2005. He educated in the same institution and completed the doctor’s course in the Department of Medical Science in 2012.
In addition to the role of TMDU, Dr. Kano also has an impressive external occupation. From 2014 to 2019, he served as a postdoctoral researcher at the Department of Medicine and Pathology at the University of Toronto for five years. This international experience has enriched his research and clinical skills, especially in genomic biology, tumor diagnosis and therapy, tumor biology, gastrointestinal disease, gastrointestinal disease, gastrointestinal disease. And general medicine medicine. His professional knowledge in Kras biology and targeted therapy emphasized to his major contribution to his major contribution to his publication, which proven publications in famous journals such as PNA and cancer research.
The contribution of Dr. Cano to the field of oncology emphasizes his commitment to promote cancer genome medicine and development targeted therapy. When he led innovative research and provided comprehensive patient care, his work continued to affect Japan and the international medical community.
Dr. Nito on the sea It is a specialized dentist (DS) specializing in oral and maxillofacial surgery. At present, he is a doctoral student at Tokyo Medical and Dental University, graduates of medicine and dental science, and focuses on health science and biomedical engineering. Since April 2021, he has been actively participating in comprehensive genetic analysis projects on oral cancer. His research aims to improve the understanding and treatment of oral cancer through detailed genome research.
